Most Popular Cardiology Technology Content in October 2018

The FDA cleared an additional indication for rivaroxaban (Xarelto) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD).

The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban (Xarelto) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD). This was the top story opened by readers in October 2018.

November 1, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of October 2018. This is based on website analytics of the month’s record high 254,242 pageviews:

1. FDA Clears Rivaroxaban to Reduce the Risk of Major Cardiovascular Events

2. CT Calcium Scoring Becoming a Key Risk Factor Assessment

3. VIDEO: Comparison Between Watchman vs. Amulet LAA Occluders — Interview with Ashish Pershad, M.D.,

4. How Advances in Wearable Cardiac Monitors Improve the Patient and Clinician Experience

5. VIDEO: Editor’s Choice of the Most Innovative New Technology at TCT 2018

6. Ohio State First in U.S. to Test Shunt Device for Heart Failure

7. FDA Clears HeartMate 3 for Heart Failure Patients Not Eligible for Transplant

8. Longer Continuous Ambulatory Cardiac Monitoring Enables More Comprehensive Evaluation of Atrial Fibrillation

9. FAST-FFR Trial of FFR-angio Technology Meets Primary Endpoint, Exceeded Performance Goals

10. VIDEO: How to Achieve Hemostasis With Large Bore Device Access — Interview with Philippe Genereux, M.D.

11. FFR-CT is Ready for Prime-time Evaluation of Coronary Disease

12. VIDEO: Implementation of New Cardiovascular Technologies at Baylor Scott White Heart Hospital — Intervioew with Jeffrey Schussler, M.D.